This company listing is no longer active
Resumen de acción ESP
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de Esperite N.V.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0092 |
| 52 Week High | €0.032 |
| 52 Week Low | €0.009 |
| Beta | 0 |
| 1 Month Change | -22.03% |
| 3 Month Change | -56.60% |
| 1 Year Change | -66.67% |
| 3 Year Change | -82.34% |
| 5 Year Change | -98.37% |
| Change since IPO | -99.87% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| ESP | NL Biotechs | Mercado NL | |
|---|---|---|---|
| 7D | 0% | 2.8% | 0.4% |
| 1Y | -66.7% | -10.6% | 17.7% |
Rentabilidad vs. Industria: ESP underperformed the Dutch Biotechs industry which returned -19.8% over the past year.
Rentabilidad vs. Mercado: ESP underperformed the Dutch Market which returned -27.8% over the past year.
Volatilidad de los precios
| ESP volatility | |
|---|---|
| ESP Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in NL Market | 8.1% |
| 10% least volatile stocks in NL Market | 2.3% |
Precio estable de las acciones: ESP's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: ESP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Dutch stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | n/a | Frédéric Amar | www.esperite.com |
Resumen de fundamentos de Esperite N.V.
| Estadísticas fundamentales de ESP | |
|---|---|
| Capitalización bursátil | €481.41k |
| Beneficios(TTM) | -€18.72m |
| Ingresos (TTM) | €13.57m |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está ESP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ESP | |
|---|---|
| Ingresos | €13.57m |
| Coste de los ingresos | €4.50m |
| Beneficio bruto | €9.07m |
| Otros gastos | €27.78m |
| Beneficios | -€18.72m |
Últimos beneficios comunicados
Jun 30, 2018
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0.0% |
¿Cómo se ha desempeñado ESP a largo plazo?
Ver rendimiento histórico y comparativa